The ubiquitin system plays an important role in essentially every cellular process, regulating numerous pathways ranging from development, transcription, DNA damage response, cell cycle, and signal transduction. Its best studied role involves removal of faulty proteins or those that are not necessary anymore. Aberrations in the ubiquitin system have been implicated in various pathologies including cancer, where specific mutations in E3 ligases such as Mdm2, pVHL, and BRCA1 have been linked to disease progression, prognosis, and resistance to drugs. Yet, there are hundreds of E3 ligases in the human genome and our knowledge of their target proteins and their dynamic regulation in the cellular environment is largely limited. In addition, fundamental questions related to recognition and specificity in ubiquitin conjugation remain unanswered. It is thus of major importance to characterize the ubiquitin landscape under various cellular conditions, and study how the regulatory network is altered in health and disease. To do so, analytical tools that allow identification of ubiquitin substrates, the conjugation and removal of ubiquitin, and the nature of specific ubiquitin linkages that are formed are needed. In this mini-review, we discuss common proteomic methodologies applied to studying the ubiquitome, and specifically focus on our recently developed post-translational modification (PTM) profiling approach. PTM profiling is a functional assay, amenable to biochemical manipulation, which allows the detection of protein modifications in a high-throughput manner. We discuss in detail the advantages and limitations of this system, focusing primarily on examples for analyzing the ubiquitin system in cancer. Uncovering the intricate signaling dynamics governed by and regulating ubiquitin modifications should clearly evolve into a new paradigm in understanding the molecular basis of malignant transformation and the development of novel therapeutic modalities.
SchulmanBA. Twists and turns in ubiquitin-like protein conjugation cascades. Protein Sci2011; 20: 1941–54.
2.
HochstrasserM. Origin and function of ubiquitin-like proteins. Nature2009; 458: 422–9.
3.
KirkinVDikicI. Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr Opin Cell Biol2007; 19: 199–205.
4.
van der VeenAGPloeghHL. Ubiquitin-like proteins. Annu Rev Biochem2012; 81: 323–57.
5.
BedfordLLoweJDickLRMayerRJBrownellJE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov2011; 10: 29–46.
6.
CiechanoverASchwartzAL. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim Biophys Acta2004; 1695: 3–17.
7.
HershkoACiechanoverA. The ubiquitin system. Annu Rev Biochem1998; 67: 425–79.
8.
WilliamsonAWernerARapeM. The colossus of ubiquitylation: decrypting a cellular code. Mol Cell2013; 49: 591–600.
9.
YenH-CSXuQChouDMZhaoZElledgeSJ. Global protein stability profiling in mammalian cells. Science2008; 322: 918–23.
10.
KirkpatrickDSDenisonCGygiSP. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nat Cell Biol2005; 7: 750–7.
11.
PengJSchwartzDEliasJEThoreenCCChengDMarsischkyGRoelofsJFinleyDGygiSP. A proteomics approach to understanding protein ubiquitination. Nat Biotechnol2003; 21: 921–6.
12.
BeltraoPAlbanèseVKennerLRSwaneyDLBurlingameAVillénJLimWAFraserJSFrydmanJKroganNJ. Systematic functional prioritization of protein posttranslational modifications. Cell2012; 150: 413–25.
13.
EmanueleMJEliaAEHXuQThomaCRIzharLLengYGuoAChenY-NRushJHsuPW-CYenH-CSElledgeSJ. Global identification of modular cullin-RING ligase substrates. Cell2011; 147: 459–74.
14.
MirzaeiHRogersRSGrimesBEngJAderemAAebersoldR. Characterizing the connectivity of poly-ubiquitin chains by selected reaction monitoring mass spectrometry. Mol Biosyst2010; 6: 2004–14.
15.
WagnerSABeliPWeinertBTNielsenMLCoxJMannMChoudharyC. A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics2011; 10: M111.013284–M111.013284.
16.
KimWBennettEJHuttlinELGuoALiJPossematoASowaMERadRRushJCombMJHarperJWGygiSP. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell2011; 44: 325–40.
17.
HendriksIAD’SouzaRCJYangBVerlaan-de VriesMMannMVertegaalACO. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol2014; 21: 927–36.
18.
SowaMEBennettEJGygiSPHarperJW. Defining the human deubiquitinating enzyme interaction landscape. Cell2009; 138: 389–403.
19.
XuGPaigeJSJaffreySR. Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling. Nat Biotechnol2010; 28: 868–73.
20.
VenneASKolliparaLZahediRP. The next level of complexity: crosstalk of posttranslational modifications. Proteomics2014; 14: 513–24.
21.
ZhuHBilginMBanghamRHallDCasamayorABertonePLanNJansenRBidlingmaierSHoufekTMitchellTMillerPDeanRAGersteinMSnyderM. Global analysis of protein activities using proteome chips. Science2001; 293: 2101–5.
22.
HultschigCKreutzbergerJSeitzHKonthurZBüssowKLehrachH. Recent advances of protein microarrays. Curr Opin Chem Biol2006; 10: 4–10.
23.
SpurrierBRamalingamSNishizukaS. Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc2008; 3: 1796–808.
24.
MasudaMYamadaT. Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine. Biochim Biophys Acta2015; 1854: 651–7.
25.
MacBeathGSchreiberSL. Printing proteins as microarrays for high-throughput function determination. Science2000; 289: 1760–3.
26.
ZhuHKlemicJFChangSBertonePCasamayorAKlemicKGSmithDGersteinMReedMASnyderM. Analysis of yeast protein kinases using protein chips. Nat Genet2000; 26: 283–9.
27.
NomuraDKDixMMCravattBF. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer2010; 10: 630–8.
28.
GuptaRKusBFladdCWasmuthJTonikianRSidhuSKroganNJParkinsonJRotinD. Ubiquitination screen using protein microarrays for comprehensive identification of Rsp5 substrates in yeast. Mol Syst Biol2007; 3: 116–116.
29.
AndrewsPSSchneiderSYangEMichaelsMChenHTangJEmkeyR. Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays. Assay Drug Dev Technol2010; 8: 471–87.
30.
MerblYKirschnerMW. Large-scale detection of ubiquitination substrates using cell extracts and protein microarrays. Proc Natl Acad Sci USA2009; 106: 2543–8.
31.
MerblYKirschnerMW. Post-translational modification profiling – a high-content assay for identifying protein modifications in mammalian cellular systems. Curr Protoc Protein Sci2014; 77: 27.8.1–27.8.13.
32.
MerblYKirschnerMW. Protein microarrays for genome-wide posttranslational modification analysis. Wiley Interdiscip Rev Syst Biol Med2011; 3: 347–56.
33.
MerblYRefourPPatelHSpringerMKirschnerMW. Profiling of ubiquitin-like modifications reveals features of mitotic control. Cell2013; 152: 1160–72.
34.
WilliamsonAJinLRapeM. Preparation of synchronized human cell extracts to study ubiquitination and degradation. Methods Mol Biol2009; 545: 301–12.
35.
OlsenJVMannM. Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol Cell Proteomics2013; 12: 3444–52.
36.
ZhangBWangJWangXZhuJLiuQShiZChambersMCZimmermanLJShaddoxKFKimSDaviesSRWangSWangPKinsingerCRRiversRCRodriguezHTownsendRREllisMJCCarrSATabbDLCoffeyRJSlebosRJCLieblerDC. Proteogenomic characterization of human colon and rectal cancer. Nature2014; 513: 382–7.
37.
BernassolaFKarinMCiechanoverAMelinoG. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell2008; 14: 10–21.
38.
HauptYMayaRKazazAOrenM. Mdm2 promotes the rapid degradation of p53. Nature1997; 387: 296–9.
39.
CarranoACEytanEHershkoAPaganoM. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitorp27. Nat Cell Biol1999; 1: 193–9.
40.
HershkoDBornsteinGBen-IzhakOCarranoAPaganoMKrauszMMHershkoA. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer2001; 91: 1745–51.
41.
KossatzUDietrichNZenderLBuerJMannsMPMalekNP. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev2004; 18: 2602–7.
42.
Montes de Oca LunaRWagnerDSLozanoG. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature1995; 378: 203–6.
43.
ScheffnerMHuibregtseJMVierstraRDHowleyPM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell1993; 75: 495–505.
44.
Kravtsova-IvantsivYShomerICohen-KaplanVSnijderBSuperti-FurgaGGonenHSommerTZivTAdmonANaroditskyIJbaraMBrikAPikarskyEKwonYTDoweckICiechanoverA. KPC1-mediated ubiquitination and proteasomal processing of NF-κB1 p105 to p50 restricts tumor growth. Cell2015; 161: 333–47.
45.
de BiePCiechanoverA. Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ2011; 18: 1393–402.
46.
ItoTAndoHSuzukiTOguraTHottaKImamuraYYamaguchiYHandaH. Identification of a primary target of thalidomide teratogenicity. Science2010; 327: 1345–50.
47.
VassilevLTVuBTGravesBCarvajalDPodlaskiFFilipovicZKongNKammlottULukacsCKleinCFotouhiNLiuEA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science2004; 303: 844–8.
48.
IssaevaNBozkoPEngeMProtopopovaMVerhoefLGGCMasucciMPramanikASelivanovaG. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med2004; 10: 1321–8.
49.
Fristedt DuvefeltCLubSAgarwalPArngårdenLHammarbergAMaesKVan ValckenborghEVanderkerkenKJernberg WiklundH. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 – implications for a combinatorial treatment. Oncotarget2015; 6: 20621–35.
50.
RamakrishnanVPainulyUKimlingerTHaugJRajkumarSVKumarS. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia2014; 28: 1519–28.
51.
ChauhanDNeriPVelankarMPodarKHideshimaTFulcinitiMTassonePRajeNMitsiadesCMitsiadesNRichardsonPZawelLTranMMunshiNAndersonKC. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood2007; 109: 1220–7.
52.
ChenQXieWKuhnDJVoorheesPMLopez-GironaAMendyDCorralLGKrenitskyVPXuWMoutouh-de ParsevalLWebbDRMercurioFNakayamaKINakayamaKOrlowskiRZ. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood2008; 111: 4690–9.
53.
LubSMaesKMenuEBruyneEDeVanderkerkenKVanValckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget2015; 7: 6521–37.
